The Ebola virus outbreak in Western Africa controlled a lot of the reports in 2014. The highly communicable pathogen spreads quickly and kills over half of those people who become infected, resulting in heavy panics across multiple continents. While the vast majority of the dead are in Africa, health workers did bring the virus home to other states and continents.
For all the bad news and focus upon doomsday scenarios on what the pathogen could do, there are actually dome commercial benefits of Ebola virus break outs. The industrial benefits principally breakdown between non-profit or govt groups and for-profit biotechnology companies.
Government or help organizations like the Red Cross or the CDC tend to see increases in funding in events like these. The economic advantages to them are direct and help out those on the ground suffering or aiding and containing an onset.
This containment keeps commercial disruption when funding is acceptable to turn the tide of an onset.
The longer term economic benefits of Ebola virus outbursts are biotech corporations working on vaccines or medicines that might improve survival rates of those infected by Ebola. One such firm is Tekmira, which has been given blessings by the FDA to widen testing on in its experimental Ebola drug for bigger scale controlled trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that might see increased business in the future if their own Ebola drugs and medications turn out to be of value.
While the 2014 Ebola outbreak is the first to have caught world attention as much as it probably did, it was barely the 1st breakout. Others have occurred, and more will occur in the future. Any business which has an Ebola drug or vaccine on the market that proves effective can be certain to see a rise in business in the future.
For all the bad news and focus upon doomsday scenarios on what the pathogen could do, there are actually dome commercial benefits of Ebola virus break outs. The industrial benefits principally breakdown between non-profit or govt groups and for-profit biotechnology companies.
Government or help organizations like the Red Cross or the CDC tend to see increases in funding in events like these. The economic advantages to them are direct and help out those on the ground suffering or aiding and containing an onset.
This containment keeps commercial disruption when funding is acceptable to turn the tide of an onset.
The longer term economic benefits of Ebola virus outbursts are biotech corporations working on vaccines or medicines that might improve survival rates of those infected by Ebola. One such firm is Tekmira, which has been given blessings by the FDA to widen testing on in its experimental Ebola drug for bigger scale controlled trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that might see increased business in the future if their own Ebola drugs and medications turn out to be of value.
While the 2014 Ebola outbreak is the first to have caught world attention as much as it probably did, it was barely the 1st breakout. Others have occurred, and more will occur in the future. Any business which has an Ebola drug or vaccine on the market that proves effective can be certain to see a rise in business in the future.
About the Author:
my name is alfred obi I've been a biological scientist for years teaching individuals on ebola virus disease update and ebola virus disease which has influenced most states in africa be at liberty to visit my website for your free protecting gear on ebola thanks.
